Lung Cancer Therapy Market is expected to reach US$ 80,493.84 million by 2030

Non-Small Cell Lung Cancer Segment Held Largest Share of Lung Cancer Therapy Market in 2022

According to our new research study on “Lung Cancer Therapy Market Forecast to 2030 – Global Analysis – by Therapy Type, Indication, and End User,” the lung cancer therapy market is expected to grow from US$ 31,018.32 million in 2022 to US$ 80,493.84 million by 2030; it is anticipated to record a CAGR of 12.7% from 2022 to 2030. The report emphasizes the trends prevalent in the global lung cancer therapy market, along with drivers and deterrents affecting its growth.

The lung cancer therapy market, by indication, is segmented into non-small cell lung cancer and small cell lung cancer. In 2022, the non-small cell lung cancer segment held a larger market share. The segment is further expected to record a higher CAGR during 2022–2030. Non-small cell lung cancer (NSCLC) occurs when abnormal cells proliferate in lung tissues. There are three primary forms of NSCLC cancer—adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Other types of NSCLC include adenosquamous carcinoma and sarcomatoid carcinoma, which are substantially less frequent in occurrence. NSCLC develops at a slower pace than small-cell lung cancer. It usually spreads to other parts of the patient's body by the time it is diagnosed. Therefore, early diagnosis and treatment are crucial. According to the National Foundation for Cancer Research, NSCLC accounts for approximately 9 out of every 10 diagnoses. As per the same source, large-cell undifferentiated carcinoma lung cancer reports for ~10–15% of all NSCLC diagnoses. This type of lung cancer can originate in any part of the lung, and is also known to grow and spread quickly. Small-cell lung cancer (SCLC) usually initiates in the bronchi or the airways, which lead from the trachea, enter the lungs, and then branch off progressively into tiny air sacs called alveoli. After affecting the bronchi, SCLC quickly proliferates and spreads to other parts of the body, including the lymph nodes. According to the National Foundation for Cancer Research, this type of lung cancer represents less than 20% of lung cancers and is commonly caused by tobacco smoking. SCLC is categorized into small cell carcinoma and combined small cell carcinoma. These two categories differ on the basis of small cells when scanned under a microscope. Small cell carcinoma is the prevalent type of SCLC and SCLC appears flat under a microscope, resembling oats. Combined small-cell carcinoma refers to a tumor comprising small-cell carcinoma cells and a small number of NSCLC cells.

Lung Cancer Therapy Market, by Region, 2022 (%)

The lung cancer therapy market, by end user, is segmented into hospitals, oncology clinics, research centers and others. In 2022, the hospitals segment held the largest market share. However, the oncology clinics segment is expected to record the highest CAGR during 2022–2030. Hospitals are the primary healthcare centers approached by patients for their first aid and treatment. The number of patients visiting hospitals is comparatively higher than other healthcare centers. These centers offer various services and provide good-quality treatment to patients. In many hospitals, treatment fees are reimbursed; also, medicines are easily available in these healthcare centers. The implementation of advanced treatment technologies in hospitals has paved the way for improved and early detection of disease, as well as supported research related to disease treatment. Moreover, the affordability and awareness of lung cancer treatments provided in hospitals is increasing gradually with the expanding coverage of health insurance policies, resulting in decreasing out-of-pocket costs.

Hospitals are complex organizations that provide healthcare services such as disease screening, diagnosis, and treatment with the help of modernized equipment. The increasing number of admissions in hospitals, coupled with the high prevalence of lung cancer, is anticipated to fuel the growth of the hospital segment in the lung cancer treatment market during the forecast period.

Medtronic PLC, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Meiji Seika Pharma Co Ltd, Advanz Pharma Corp, and Olympus Corp are a few of the key companies operating in the lung cancer therapy market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name.

The report segments the lung cancer therapy market as follows: 

The lung cancer therapy market, by vaccine type, is bifurcated into noninvasive and minimally invasive. The minimally invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. In 2022, the non-invasive therapy segment held a larger market share. Further, the minimally invasive segment is expected to record a faster CAGR during 2022–2030. The lung cancer therapy market, by indication, is bifurcated into non-small cell lung cancer and small cell lung cancer. In 2022, the non-small cell lung cancer segment held a larger market share. The non-small cell lung cancer segment is expected to register a faster CAGR during 2022–2030. The lung cancer therapy market, by end user, is segmented into hospitals, oncology clinics, research centers, and others. In 2022, the hospitals segment held the largest market share. However, the oncology clinics segment is expected to record the fastest CAGR during 2022–2030.

Based on geography, the lung cancer therapy market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com